{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Oxytocin",
    "short_name": "Oxytocin",
    "aliases": [
      "pitocin",
      "oxytocin injection"
    ],
    "classification": {
      "category": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "needs_prescription": false,
      "notes": "Classification describes what Oxytocin is and the general domain where it appears."
    },
    "status": {
      "category": "approved_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-19",
      "human_use_note": "Status reflects how Oxytocin appears in clinical literature and/or real-world contexts. This is descriptive only."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "unknown",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Risk scoring reflects evidence quality, adverse-signal plausibility, and uncertainty. Limited data increases uncertainty.",
      "risk_score": 5
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Oxytocin is a bioactive compound discussed in research and/or clinical contexts. This entry summarizes what it is, what it is studied for, and key evidence limitations without providing protocols.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "unit": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "min": null,
          "max": null,
          "frequency": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "duration": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": [],
      "current_outlook_bullets": [
        "a bioactive compound discussed in research and/or clinical contexts",
        "this entry summarizes what it is, what it is studied for, and key evidence limitations without providing protocols",
        "general recovery and resilience interest (anecdotal)",
        "common biohacker curiosity due to community reports",
        "interest in mechanisms suggested by early evidence",
        "used in goal-based stacking discussions (anecdotal)",
        "exploration in wellness communities despite evidence limits"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "source_type": "pubmed",
        "source_id": "E1",
        "url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "published_date": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "evidence_grade": "unknown",
        "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-19",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for Oxytocin",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      }
    ],
    "needs_prescription": true,
    "meta": {
      "priority": "normal",
      "notes_seed": "FDA-approved oxytocin (Rx) uterotonic; include only label-level indications; no protocols."
    },
    "topics": {
      "primary": [
        "topic_hormonal_endocrine"
      ]
    },
    "slug": "oxytocin",
    "practical": {
      "schema_version": "practical_block_v1",
      "bottom_line": "Oxytocin is a human hormone used clinically in specific obstetric settings. In non-clinical markets it is discussed for social bonding and mood effects, but the biggest risks are inappropriate use, contraindicated medical situations, and lack of supervision.",
      "benefits": [
        "Social bonding and connection interest in some communities",
        "Stress and mood support interest in some communities",
        "Clinical relevance in obstetric care contexts"
      ],
      "side_effects_common": [
        "Headache",
        "Nausea",
        "Dizziness",
        "Fatigue"
      ],
      "side_effects_serious": [
        "Chest pain, fainting, or severe shortness of breath",
        "Severe confusion or severe agitation",
        "Severe uterine cramping in pregnancy"
      ],
      "who_should_be_cautious": [
        "Pregnancy or trying to conceive",
        "Postpartum complications or significant gynecologic history",
        "Significant cardiovascular disease",
        "Seizure disorders",
        "Children and adolescents"
      ]
    }
  },
  "canonical_name": "Oxytocin",
  "interactions": {
    "drug_classes": [
      "neuropeptide-cns-context"
    ],
    "supplement_classes": [],
    "peptides": []
  },
  "practical": {
    "schema_version": "practical_block_v1",
    "bottom_line": "Oxytocin is a human hormone used clinically in specific obstetric settings. In non-clinical markets it is discussed for social bonding and mood effects, but the biggest risks are inappropriate use, contraindicated medical situations, and lack of supervision.",
    "benefits": [
      "Social bonding and connection interest in some communities",
      "Stress and mood support interest in some communities",
      "Clinical relevance in obstetric care contexts"
    ],
    "side_effects_common": [
      "Headache",
      "Nausea",
      "Dizziness",
      "Fatigue"
    ],
    "side_effects_serious": [
      "Chest pain, fainting, or severe shortness of breath",
      "Severe confusion or severe agitation",
      "Severe uterine cramping in pregnancy"
    ],
    "who_should_be_cautious": [
      "Pregnancy or trying to conceive",
      "Postpartum complications or significant gynecologic history",
      "Significant cardiovascular disease",
      "Seizure disorders",
      "Children and adolescents"
    ]
  }
}
